Literature DB >> 19096856

[Vasculitis. Treatment outcome parameters].

P M Aries1, A Gause.   

Abstract

The definition of outcome parameters has improved the care of vasculitis patients dramatically in recent decades. In the first phase of joint European studies, disease stages and activity were defined. In the second and third phases results of the randomized and controlled trials were summarized and published as European recommendations for the care of small and large vessel vasculitis. Irrespective of the type of vasculitis, inducing remission, maintaining remission and preventing disease- and therapy-related complications are the main outcome criteria.

Entities:  

Mesh:

Year:  2009        PMID: 19096856     DOI: 10.1007/s00393-008-0358-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  24 in total

1.  Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis.

Authors:  Carlo Salvarani; Luca Cimino; Pierluigi Macchioni; Dario Consonni; Fabrizio Cantini; Gianluigi Bajocchi; Nicolò Pipitone; Maria Grazia Catanoso; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2005-04-15

2.  A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).

Authors:  R F Spiera; H J Mitnick; M Kupersmith; M Richmond; H Spiera; M G Peterson; S A Paget
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

3.  Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register.

Authors:  Eva Reinhold-Keller; Karen Herlyn; Rosemarie Wagner-Bastmeyer; Wolfgang L Gross
Journal:  Arthritis Rheum       Date:  2005-02-15

4.  Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.

Authors:  Carlo Salvarani; Fabrizio Cantini; Laura Niccoli; Pierluigi Macchioni; Dario Consonni; Gianluigi Bajocchi; Marco Vinceti; Maria Grazia Catanoso; Lia Pulsatelli; Riccardo Meliconi; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2005-02-15

5.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

6.  Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.

Authors:  Anne Proven; Sherine E Gabriel; Carlos Orces; W Michael O'Fallon; Gene G Hunder
Journal:  Arthritis Rheum       Date:  2003-10-15

7.  Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.

Authors:  Anthony Booth; Lorraine Harper; Tariq Hammad; Paul Bacon; Megan Griffith; Jeremy Levy; Caroline Savage; Charles Pusey; David Jayne
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

8.  High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate.

Authors:  Eva Reinhold-Keller; Claudia O E Fink; Karen Herlyn; Wolfgang L Gross; Kirsten De Groot
Journal:  Arthritis Rheum       Date:  2002-06-15

9.  Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.

Authors:  C Metzler; N Miehle; K Manger; C Iking-Konert; K de Groot; B Hellmich; W L Gross; E Reinhold-Keller
Journal:  Rheumatology (Oxford)       Date:  2007-05-22       Impact factor: 7.580

10.  Risk factors for early visual deterioration in temporal arteritis.

Authors:  Tobias Loddenkemper; Pankaj Sharma; I Katzan; Gordon T Plant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05-15       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.